Fundamental dimension Equity attribute | DQWSPeer $0.0840.00% Cap $17.38MP/E -70.0x QuantScore35/100 | ATPCPeer $1.40▼-1.76% Cap $1.40MP/E -1.2x QuantScore28/100 | BIOELeader $0.420.00% Cap $16.63MP/E 11.3x QuantScore77/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
50/100 |
25/100 |
73/100 |
Valuation Multiples, PEG & DCF upside | 33/100 | 0/100 | 77/100 |
Health Piotroski, Altman Z, leverage & liquidity | 40/100 | 50/100 | 60/100 |
Growth Revenue / earnings growth & margins | 16/100 | 38/100 | 100/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | -70.0x | -1.2x | 11.3x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | -122.4x | -0.6x | 11.1x |
Price / Sales | 9.2x | 1.3x | 5.7x |
Price / Free Cash Flow | -69.5x | -1.4x | 15.5x |
PEG ratio | 0.70 | -0.00 | 0.01 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 1 / 9 | 2 / 9 | 6 / 9 |
Altman Z-Score | 14.59 (Safe) | 0.38 (Distress) | 4.46 (Safe) |
Total debt / equity | -31.98 | 0.00 | 0.67 |
Quick ratio | 0.8x | 8.4x | 0.4x |
Interest coverage | -124.3x | — | 706.6x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | -6.2% | +15.2% | +485.8% |
Net income growth YoY | -445.9% | +7.7% | +168.5% |
Gross margin (TTM) | 25.5% | 58.9% | 69.7% |
Operating margin (FY) | -2.9% | -213.7% | 47.4% |
FCF margin (FY) | -4.6% | -158.4% | 82.7% |
5. Trailing price performancePrice change over period |
1M return | 0.0% | -37.7% | +130.8% |
3M return | +171.0% | -43.3% | +55.6% |
6M return | -1.2% | -39.1% | -6.7% |
Year to date | +115.4% | -73.8% | +600.0% |
1Y return | +162.5% | -97.8% | +508.7% |
3Y return | -16.8% | -99.9% | -17.6% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $0.0163 -80.6% premium | $-69.97 -5115.5% premium | $-0.1693 -140.3% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |